Who
Jon Faiz Kayyem
Director
Company insider
Files Form 4 as: Director, Inhibrx Biosciences; Director, Biodesix; Director, Inhibrx; SVP, Research & Development, GenMark Diagnostics; 10% owner, Repros Therapeutics.
In numbers
- Trades disclosed
- 177
- Buys
- 20
- Sells
- 68
- Bought
- $14.2M
- Sold
- $4.2M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 4 Jan 2008
- Last trade
- 23 Sep 2026
- Last filed
- 23 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Sep 2026filed 23 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $500K5,000 at $100.00 | filing |
| 23 Sep 2026filed 23 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $500K5,000 at $100.00 | filing |
| 16 Sep 2026filed 17 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $500K5,000 at $100.00 | filing |
| 16 Sep 2026filed 17 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $500K5,000 at $100.00 | filing |
| 8 Sep 2026filed 8 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $568K5,000 at $113.52 | filing |
| 8 Sep 2026filed 8 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $568K5,000 at $113.52 | filing |
| 3 Jun 2026filed 18 Sep 2026 | INBX Inhibrx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 3 Jun 2026filed 18 Sep 2026 | INBX Inhibrx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | INBX Inhibrx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | INBX Inhibrx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —5,443 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —6,354 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —5,443 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —6,354 at $0.00 | filing |
| 28 May 2025filed 29 May 2025 | INBX Inhibrx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 20 May 2025filed 22 May 2025 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —68,621 at $0.00 | filing |
| 20 May 2025filed 22 May 2025 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —42,010 at $0.00 | filing |
| 27 Mar 2025filed 28 Mar 2025 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Code G | —90,000 at $0.00 | filing |
| 16 Dec 2024filed 17 Dec 2024 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Code G | —500,000 at $0.00 | filing |
| 16 Dec 2024filed 17 Dec 2024 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Code G | —250,000 at $0.00 | filing |
News
Analyzing Inhibrx Biosciences (NASDAQ:INBX) and Ligand Pharmaceuticals (NASDAQ:LGND)INBX · tickerreport.com · 23 Oct 2026Insider Buying: Inhibrx Biosciences (NASDAQ:INBX) CEO Acquires $848,982.40 in StockINBX · themarketsdaily.com · 17 Oct 2026Inhibrx Biosciences (NASDAQ:INBX) CEO Purchases $848,982.40 in StockINBX · dailypolitical.com · 15 Oct 2026
0 headlines in the last 90 days name Jon Faiz Kayyem; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.